Michiel J Thomeer

List of Publications by Year
in descending order

69	6,269	201575 27	114418 63
papers	citations	h-index	g-index

77	77	77	6922
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Impact of acute exacerbations of COPD on patients' health status beyond pulmonary function: A scoping review. Pulmonology, 2023, 29, 518-534.	1.0	11
2	Remote patient monitoring in COVID-19: a critical appraisal. European Respiratory Journal, 2022, 59, 2102697.	3.1	9
3	Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics. International Journal of Molecular Sciences, 2022, 23, 5602.	1.8	3
4	Changes in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review. Metabolites, 2022, 12, 545.	1.3	4
5	Plausibility and redundancy analysis to select FDGâ€PET textural features in nonâ€small cell lung cancer. Medical Physics, 2021, 48, 1226-1238.	1.6	15
6	Detection of Lung Cancer via Blood Plasma and 1H-NMR Metabolomics: Validation by a Semi-Targeted and Quantitative Approach Using a Protein-Binding Competitor. Metabolites, 2021, 11, 537.	1.3	6
7	Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET. EJNMMI Research, 2021, 11, 4.	1.1	15
8	Fever and an abnormal chest X-ray during the COVID-19 pandemic. Respiratory Medicine Case Reports, 2020, 31, 101167.	0.2	0
9	Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?. European Respiratory Journal, 2020, 56, 2001201.	3.1	50
10	Correlations between the metabolic profile and 18F-FDG-Positron Emission Tomography-Computed Tomography parameters reveal the complexity of the metabolic reprogramming within lung cancer patients. Scientific Reports, 2019, 9, 16212.	1.6	7
11	The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism. Frontiers in Oncology, 2019, 9, 1215.	1.3	97
12	Glutamine Addiction and Therapeutic Strategies in Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 252.	1.8	82
13	Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. Cancer Treatment and Research Communications, 2018, 15, 7-12.	0.7	19
14	Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer, 2018, 115, 49-55.	0.9	38
15	Diagnosis of Lung Cancer: What Metabolomics Can Contribute. , 2018, , .		0
16	The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer. BMC Cancer, 2018, 18, 868.	1.1	13
17	Metabolic phenotyping of human plasma by ¹Hâ€NMR at high and medium magnetic field strengths: a case study for lung cancer. Magnetic Resonance in Chemistry, 2017, 55, 706-713.	1.1	13
18	Sarcoidosis around the Globe. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 393-403.	0.8	6

#	Article	IF	Citations
19	Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma. Journal of Thoracic Oncology, 2016, 11, 516-523.	0.5	54
20	Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). Journal of Thoracic Oncology, 2016, 11, 85-93.	0.5	26
21	Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types?. Annals of Oncology, 2016, 27, 178-184.	0.6	24
22	Are Randomized Controlled Trials the (G)old Standard? From Clinical Intelligence to Prescriptive Analytics. Journal of Medical Internet Research, 2016, 18, e185.	2.1	39
23	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1458-1467.	0.5	50
24	Metabolomics a Novel Biomarker in Lung Cancer. Journal of Thoracic Oncology, 2015, 10, e46.	0.5	2
25	Phenotyping human blood plasma by 1H-NMR: a robust protocol based on metabolite spiking and its evaluation in breast cancer. Metabolomics, 2015, 11, 225-236.	1.4	28
26	Influence of preanalytical sampling conditions on the 1H NMR metabolic profile of human blood plasma and introduction of the Standard PREanalytical Code used in biobanking. Metabolomics, 2015, 11, 1197-1207.	1.4	27
27	2015, big data in healthcare: for whom the bell tolls?. Critical Care, 2015, 19, 171.	2.5	8
28	Validation of 1H-Nmr-Based Metabolomics As a Tool to Detect Lung Cancer in Human Blood Plasma. Annals of Oncology, 2014, 25, iv406.	0.6	1
29	Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Annals of Oncology, 2013, 24, 986-992.	0.6	76
30	Methotrexate vs Azathioprine in Second-line Therapy of Sarcoidosis. Chest, 2013, 144, 805-812.	0.4	210
31	New Idiopathic Pulmonary Fibrosis Guidelines: Some Unresolved Questions. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 588-588.	2.5	1
32	New Idiopathic Pulmonary Fibrosis Guidelines: Some Unresolved Questions. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 588-589.	2.5	0
33	Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax, 2012, 67, 938-940.	2.7	71
34	MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.. Journal of Clinical Oncology, 2012, 30, 7013-7013.	0.8	3
35	Treatment strategies for sarcoidosis. Acta Clinica Belgica, 2012, 67, 83-7.	0.5	1
36	Newer modes of treating interstitial lung disease. Current Opinion in Pulmonary Medicine, 2011, 17, 332-336.	1.2	5

#	Article	IF	Citations
37	Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1382-1389.	2.5	390
38	Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 459-466.	2.5	367
39	Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1231-1237.	2.5	369
40	Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT.. Journal of Clinical Oncology, 2011, 29, 7002-7002.	0.8	5
41	6-Minute Walk Test Distance (6MWD) Is A Reliable, Valid, And Responsive Outcome Measure That Predicts Mortality In Patients With IPF. , 2010, , .		2
42	Clinical use of biomarkers of survival in pulmonary fibrosis. Respiratory Research, 2010, 11, 89.	1.4	28
43	Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. Experimental Lung Research, 2010, 36, 602-614.	0.5	57
44	Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial. Respiratory Research, 2009, 10, 101.	1.4	70
45	Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet, The, 2009, 374, 222-228.	6.3	464
46	Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2008, 31, 585-591.	3.1	138
47	Treatment of Idiopathic Pulmonary Fibrosis with Etanercept. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 948-955.	2.5	338
48	Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. European Respiratory Journal, 2008, 31, 1189-1196.	3.1	271
49	A New Missense Mutation in theCASRGene in Familial Interstitial Lung Disease with Hypocalciuric Hypercalcemia and Defective Granulocyte Function. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 558-559.	2.5	8
50	An Algorithm to Tackle Acute Exacerbations in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1397-1397.	2.5	33
51	CATEGORICAL DECLINES IN PERCENT PREDICTED FORCED VITAL CAPACITY (PP-FVC) ARE ASSOCIATED WITH A GRADED RISK OF DEATH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF). Chest, 2008, 134, 20S.	0.4	2
52	Hypogonadism in male outpatients with sarcoidosis. Respiratory Medicine, 2007, 101, 2502-2510.	1.3	23
53	Disseminated Mycobacterium tilburgii infection in a non-HIV-infected patient. Clinical Microbiology Newsletter, 2007, 29, 62-64.	0.4	5
54	SarcoÃ¯dose: een adembenemende aandoening. Tijdschrift Voor Geneeskunde, 2007, 63, 987-994.	0.0	0

#	Article	IF	Citations
55	External validity of randomised controlled trials in idiopathic pulmonary fibrosis. European Respiratory Journal, 2006, 27, 1072.1-1072.	3.1	2
56	A RANDOMIZED PLACEBO CONTROLLED TRIAL ASSESSING THE EFFICACY AND SAFETY OF ETANERCEPT IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF). Chest, 2005, 128, 496S.	0.4	15
57	Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax, 2005, 60, 32-38.	2.7	124
58	High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2005, 353, 2229-2242.	13.9	880
59	Classification and new developments in the pathogenesis of vasculitis. , 2005, , 50-68.		1
60	Clinical manifestation, approach to diagnosis and treatment of pulmonary vasculitis. , 2005, , 69-90.		0
61	Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment. Respiratory Medicine, 2004, 98, 567-573.	1.3	55
62	Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS. Neurology, 2003, 61, 1150-1151.	1.5	27
63	Pertechnegas lung clearance in different forms of interstitial lung disease. European Respiratory Journal, 2002, 19, 31-36.	3.1	7
64	Passage of Inhaled Particles Into the Blood Circulation in Humans. Circulation, 2002, 105, 411-414.	1.6	1,380
65	REGISTRATION OF INTERSTITIAL LUNG DISEASES BY 20 CENTRES OF RESPIRATORY MEDICINE IN FLANDERS. Acta Clinica Belgica, 2001, 56, 163-172.	0.5	118
66	Diffuse interstitiÃ«le longaandoeningen: actuele inzichten in diagnostiek en ziekteopvolging. Tijdschrift Voor Geneeskunde, 2001, 57, 953-962.	0.0	1
67	A breathless accountant who blew up balloons. Lancet, The, 1999, 354, 124.	6.3	7
68	Systemic lupus erythematosus, eosinophilia and LÃ¶fflerâ€²s endocarditis. An unusual association. European Respiratory Journal, 1999, 13, 930.	3.1	14
69	Medical thoracoscopic lung biopsy in interstitial lung disease: a prospective study of biopsy quality. European Respiratory Journal, 1999, 14, 585.	3.1	51